Drug Trial Radar · NCT03846219
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Last checked: Nov 19, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
210
Actual
Start
Jan 28, 2019
Primary completion
Apr 24, 2020
Study completion Dec 2029
Sponsor
- Lead sponsor
- Immunic AGIndustry
- Sponsor type
- Industry
- First posted
- Feb 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), 30 mg/day and 45 mg/day in the main study, cohort 1 (and 10 mg/day for the patients in the cohort 2 substudy), in patients with RRMS and evidence of active disease. The trial consists of a screening period, a blinded 24-week main treatment period, and an optional initially blinded, then open-label extended treatment period of up to 9.5 years. About 40 centers are planned to participate in Romania, Bulgaria, Ukraine, and Poland; potential additional centers in Hungary and Croatia were not used. The study started with 195 patients in the main group (cohort 1) planned to be randomized 1:1:1 to treatment with 30 mg/day or 45 mg/day IMU-838, or placebo (65 patients each) in the main treatment period. During the extended treatment period, patients were initially re-randomized so that patients previously on placebo were re-randomized 1:1 to treatment with 30 g/day or 45 mg/day IMU-838, all other patients were re-randomized to the same treatment they previously received. With approval of Protocol Version 3.0, a sub-study patient group (cohort 2) has been added with up to 60 patients, randomized to placebo or 10 mg IMU-838 for 24 weeks after which the option is available to continue into the extended treatment period and the recommended dose of 30 mg/day. However, based on discussion between investigator and patient 45 mg/day IMU-838/day may also be used.
Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
IMU-838 (30 mg/day)Drug
* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily). * Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily.
IMU-838 (45 mg/day)Drug
* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily). * Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily.
PlaceboDrug
* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards. * Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose.
IMU-838 (10 mg/day)Drug
* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily). * Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference Between 45 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI LesionsTime frame: Up to Week 24
Locations
38 sites in 4 countries. Site status is shown where the registry gives one.
MHAT Pulse AD, Department of Neurology Diseases
Blagoevgrad, Bulgaria
UMHAT "Dr.Georgi Stranski" EAD Pleven Department of Professional Diseases
Pleven, Bulgaria
MHAT "Heart and brain" EAD Pleven Department of Neurology Diseases
Pleven, Bulgaria
UMHAT " Kaspela" EOOD, Department of Neurology Diseases
Plovdiv, Bulgaria
UMHAT "Kanev Ruse", Department of General and Vascular Neurology
Rousse, Bulgaria
MHATNP "Sveti Naum" EAD, Neurology Clinic for Movement Disorders, First Department of Neurology Diseases
Sofia, Bulgaria
MHATNPsy "Sveti Naum" EAD, Intensive Therapy Clinic Of Neurology Diseases
Sofia, Bulgaria
DCC "Neoclinic" EAD, Cabinet Neurology Diseases
Sofia, Bulgaria
UMHAT "Alexandrovska" EAD, Clinic of Neurology Diseases, Department of Inherited Degenerative and Immunoinflamatori Diseases at Peripheral Nervous System
Sofia, Bulgaria
UMHAT "Sveti Ivan Rilski" EAD Sofia Clinic of Neurological Diseases
Sofia, Bulgaria
UMHAT"Alexandrovska"EAD, Department of Degenerative and Immunoinflamatory Disease of the Central Nervous System
Sofia, Bulgaria
Central Clinical Base-Medical Institute - Ministry of Interior, Neurology Clinic
Sofia, Bulgaria
Military Medical Academy - Sofia, Clinic of Neurology Diseases
Sofia, Bulgaria
Military Medical Academy, Clinic of Functional Diagnostics of Nevous System
Sofia, Bulgaria
UMHAT " Sveta Marina EAD, First Neurology Clinic
Varna, Bulgaria
Nasz Lekarz Ośrodek Badań Klinicznych
Bydgoszcz, Poland
Specjalistyczna Praktyka Lekarska Paweł Bochniak
Bydgoszcz, Poland
Indywidualna Praktyka Lekarska Prof. Konrad Rejdak
Lublin, Poland
BioResearch Group Sp. Z o.o
Nadarzyn, Poland
Centrum Medyczne NeuroProtect
Warsaw, Poland
S.C. Sana Monitoring Srl
Bucharest, Romania
Spitalul Universitar Elias Bucharesti
Bucharest, Romania
S.C. Quantum Medical Center Srl
Bucharest, Romania
Spitalul Clinic Colentina Bucharest, Neurologie 2
Bucharest, Romania
Spitalul Clinic Cai Ferate Constanta
Constanța, Romania
Chernihiv Regional Hospital, Department of Neurology
Chernihiv, Ukraine
Dnipropetrovsk Municipal Hospital #5, Neurological Department of the inflammatory and demyelinating diseases of CNS
Dnipro, Ukraine
Ukrainian State Research Institute of Medical and Social Problems of Disability of MOH of Ukraine
Dnipro, Ukraine
Regional Clinical Hospital, Department of vascular Neurology
Ivano-Frankivsk, Ukraine
Kharkiv Regional Clinical Hospital, Department of Neurology
Kharkiv, Ukraine
Institute of Neurology, Psychiatry and Narcology NAMSU
Kharkiv, Ukraine
Kyiv City Clinical Hospital #4, Department of Neurology
Kyiv, Ukraine
Volyn Regional Clinical Hospital, Department of Neurology
Lutsk, Ukraine
Poltava Regional Clinical Hospital n.a. Sklifosovskyi, Department of Neurology
Poltava, Ukraine
Regional Clinical Centre of Neurosurgery and Neurology, Department #2
Uzhhorod, Ukraine
Vinnytsya Regional Psychoneurology Hospital n.a. Yushchenko, Department of Neurology #3
Vinnytsia, Ukraine
City Clinical Hospital #2, Department of Neurology
Zaporizhzhya, Ukraine
Zaporizhzhya Regional Clinical Hospital, Department of Neurology #1
Zaporizhzhya, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.